home · filing · 0001846253-25-000034
8-K filed April 21, 2025, 7:59 PM ET
ticker OABI
CIK 0001846253
leadership
confidence high
sentiment neutral
materiality 0.35
OmniAb appoints two new independent directors; Sarah Boyce resigns
OmniAb, Inc.
Sarah Boyce resigned from Board and all committees effective April 18; no disagreement with company.
Steven C. Crouse and Philip J. Gotwals appointed as Class II directors, terms expiring at 2027 annual meeting.
Crouse (Bio-Techne SVP) and Gotwals (former Novartis BD head) bring life sciences and biopharma expertise.
Each received initial equity grants: RSUs for 40,000 shares and options for 80,000 shares.
Board size increased from six to seven; new directors deemed independent under Nasdaq rules.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Steven C. Crouse
Director
Effective 2025-04-18
Filed April 21, 2025, 7:59 PM ET
the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board
Appointed
Philip J. Gotwals
Director
Effective 2025-04-18
Filed April 21, 2025, 7:59 PM ET
the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven C. Crouse was appointed as Director at OmniAb, Inc..
Action appointed
Role Director
Exact text from the filing
the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Philip J. Gotwals was appointed as Director at OmniAb, Inc..
Action appointed
Role Director
Exact text from the filing
the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board
View on SEC.gov
Source: SEC EDGAR
accession 0001846253-25-000034
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.